These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 30692100)

  • 1. Cell-Proliferation Imaging for Monitoring Response to CDK4/6 Inhibition Combined with Endocrine-Therapy in Breast Cancer: Comparison of [
    Elmi A; Makvandi M; Weng CC; Hou C; Clark AS; Mach RH; Mankoff DA
    Clin Cancer Res; 2019 May; 25(10):3063-3073. PubMed ID: 30692100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
    Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E
    Breast Cancer Res; 2020 Aug; 22(1):87. PubMed ID: 32787886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer.
    Michaloglou C; Crafter C; Siersbaek R; Delpuech O; Curwen JO; Carnevalli LS; Staniszewska AD; Polanska UM; Cheraghchi-Bashi A; Lawson M; Chernukhin I; McEwen R; Carroll JS; Cosulich SC
    Mol Cancer Ther; 2018 May; 17(5):908-920. PubMed ID: 29483206
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Ma G; Liu C; Lian W; Zhang Y; Yuan H; Zhang Y; Song S; Yang Z
    Ann Nucl Med; 2021 May; 35(5):600-607. PubMed ID: 33689138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
    Ladd B; Mazzola AM; Bihani T; Lai Z; Bradford J; Collins M; Barry E; Goeppert AU; Weir HM; Hearne K; Renshaw JG; Mohseni M; Hurt E; Jalla S; Bao H; Hollingsworth R; Reimer C; Zinda M; Fawell S; D'Cruz CM
    Oncotarget; 2016 Aug; 7(34):54120-54136. PubMed ID: 27472462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
    Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
    Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models.
    Gough SM; Flanagan JJ; Teh J; Andreoli M; Rousseau E; Pannone M; Bookbinder M; Willard R; Davenport K; Bortolon E; Cadelina G; Gordon D; Pizzano J; Macaluso J; Soto L; Corradi J; Digianantonio K; Drulyte I; Morgan A; Quinn C; Békés M; Ferraro C; Chen X; Wang G; Dong H; Wang J; Langley DR; Houston J; Gedrich R; Taylor IC
    Clin Cancer Res; 2024 Aug; 30(16):3549-3563. PubMed ID: 38819400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
    Andreano KJ; Wardell SE; Baker JG; Desautels TK; Baldi R; Chao CA; Heetderks KA; Bae Y; Xiong R; Tonetti DA; Gutgesell LM; Zhao J; Sorrentino JA; Thompson DA; Bisi JE; Strum JC; Thatcher GRJ; Norris JD
    Breast Cancer Res Treat; 2020 Apr; 180(3):635-646. PubMed ID: 32130619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer.
    Whittle JR; Vaillant F; Surgenor E; Policheni AN; Giner G; Capaldo BD; Chen HR; Liu HK; Dekkers JF; Sachs N; Clevers H; Fellowes A; Green T; Xu H; Fox SB; Herold MJ; Smyth GK; Gray DHD; Visvader JE; Lindeman GJ
    Clin Cancer Res; 2020 Aug; 26(15):4120-4134. PubMed ID: 32245900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and Biological Evaluation of Novel
    Song X; Gan Q; Zhang X; Zhang J
    Mol Pharm; 2019 Oct; 16(10):4213-4222. PubMed ID: 31424939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninvasive PET Imaging of CDK4/6 Activation in Breast Cancer.
    Ramos N; Baquero-Buitrago J; Ben Youss Gironda Z; Wadghiri YZ; Reiner T; Boada FE; Carlucci G
    J Nucl Med; 2020 Mar; 61(3):437-442. PubMed ID: 31481582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3'-[
    Tatum JL; Kalen JD; Jacobs PM; Riffle LA; James A; Thang L; Sanders C; Hollingshead MG; Basuli F; Shi J; Doroshow JH
    J Transl Med; 2022 Aug; 20(1):375. PubMed ID: 35982453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer.
    Belli S; Esposito D; Ascione CM; Messina F; Napolitano F; Servetto A; De Angelis C; Bianco R; Formisano L
    Cancer Lett; 2024 Jul; 593():216968. PubMed ID: 38788968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
    Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
    Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
    Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.
    Jansen VM; Bhola NE; Bauer JA; Formisano L; Lee KM; Hutchinson KE; Witkiewicz AK; Moore PD; Estrada MV; Sánchez V; Ericsson PG; Sanders ME; Pohlmann PR; Pishvaian MJ; Riddle DA; Dugger TC; Wei W; Knudsen ES; Arteaga CL
    Cancer Res; 2017 May; 77(9):2488-2499. PubMed ID: 28249908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer.
    Zhao M; Scott S; Evans KW; Yuca E; Saridogan T; Zheng X; Wang H; Korkut A; Cruz Pico CX; Demirhan M; Kirby B; Kopetz S; Diala I; Lalani AS; Piha-Paul S; Meric-Bernstam F
    Clin Cancer Res; 2021 Mar; 27(6):1681-1694. PubMed ID: 33414137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers.
    Viswanadhapalli S; Ma S; Sareddy GR; Lee TK; Li M; Gilbreath C; Liu X; Luo Y; Pratap UP; Zhou M; Blatt EB; Kassees K; Arteaga C; Alluri P; Rao M; Weintraub ST; Tekmal RR; Ahn JM; Raj GV; Vadlamudi RK
    Breast Cancer Res; 2019 Dec; 21(1):150. PubMed ID: 31878959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma.
    Nassar KW; Hintzsche JD; Bagby SM; Espinoza V; Langouët-Astrié C; Amato CM; Chimed TS; Fujita M; Robinson W; Tan AC; Schweppe RE
    Mol Cancer Ther; 2021 Oct; 20(10):2049-2060. PubMed ID: 34376578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis.
    Guo Q; Lin X; Ye L; Xu R; Dai Y; Zhang Y; Chen Q
    Target Oncol; 2019 Apr; 14(2):139-148. PubMed ID: 30941621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.